Phase 1 N=24 A Phase Ib/II in Patients With Acute Ischemic Stroke
Ischemic Stroke
Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12,551 1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
Stroke
Primary: All-cause Mortality at 1 Year (Percentage of Patients With Modified Rankin Scale (mRS) Score =6) — 11.1; 12.2 Percentage of Participants — p=0.183
N/A N=113,035 Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
Stroke
Primary: All-cause Mortality During Hospitalization of Acute Ischemic Stroke (AIS) Patients — 2.6; 0.8 Percentage of participants
N/A N=1,560 Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
Stroke
Primary: Percentage of Patients With Favourable Outcome (Modified Rankin Scale (mRS) 0-1) at 1 Year — 27.7; 23.8 Percentage of Participants — p=<0.001
Phase 3 N=458 Tenecteplase in Stroke Patients Between 4.5 and 24 Hours
THROMBOLYSIS
Primary: Ordinal Modified Rankin Scale (mRS) Score at Day 90 — 35; 31; 38; 30 Count of participants
Phase 2 N=277 Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Acute Ischemic Stroke
Primary: Percentage of Participants With Composite Global Measure of Functional Disability Excellent Outcome at Day 90 — 54.1; 41.5; 39.9 percentage of participants — p=0.086
N/A N=196 Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial
Acute Ischemic Stroke
Primary: 90-day Global Disability Assessed Via the Blinded Evaluation of Modified Rankin Score (mRS). — 17; 8; 25; 10 Participants
N/A N=54 Post Marketing Study to Evaluate the NIMBUS Device
Cerebral Stroke
Primary: Percentage of Participants With Successful Revascularization With NIMBUS Device — 68.6 Percentage of participants
N/A N=218 Safety and Efficacy of SINOMED SR for Endovascular Treatment of Acute Ischemic Stroke
Ischemic Stroke, Acute · Brain Diseases · Cerebrovascular Disorders
Primary: Number of Participants With Successful Immediate Recanalization — 105; 103 participants
Phase 2 N=126 Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke
Ischemic Stroke · Stroke · Brain Infarction
Primary: Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours of Treatment Onset — 3; 2; 22; 99 participants — p=0.053
N/A N=101 Canadian Pradaxa Acute Stroke Safety Study
Ischemic Attack, Transient · Stroke
Primary: Symptomatic Hemorrhagic Transformation Rate (PH2) — 0; 0 Participants
Phase 4 N=401 Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
Cerebral Infarction
Primary: the Rate of Patients With a Modified Rankin Scale Score of 0-1 — 109; 98; 46; 39 participants
Early Phase 1 N=453 Endovascular Recanalization and Standard Medical Management for Symptomatic Nonacute Intracranial Artery Occlusion Trial
Intracranial Artery Occlusion With Infarction
Primary: Primary Outcome — 27; 21 Participants
Phase 3 N=1,274 A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
Stroke, Acute
Primary: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) — 309; 338 Participants
N/A N=352 SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke
Acute Ischemic Stroke
Primary: Degree of Disability/Dependence as Measured by the Modified Rankin Scale (mRS) Score — 4; 5 scores on a scale
Phase 2 N=40 Safety of Intravenous Thrombolysis for Wake-up Stroke
Ischemic Stroke
Primary: Frequency of Symptomatic Hemorrhagic Transformation Safety of iv Rt-PA in Wake up Stroke Patients — 0 cases.
N/A N=35 Safety Study of Post Intravenous tPA Monitoring in Ischemic Stroke
Stroke · Ischemic Stroke
Primary: Number of Participants Needing ICU Care/Interventions Within the First 24 Hours of IV tPA Administration — 0 Participants
Phase 3 N=112 Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation
Atrial Fibrillation · Cardioversion · Cerebrovascular Stroke
Primary: Combined Clinical Thromboembolic or Hemorrhagic Event, Death or Silent Cerebral Thromboemboli — 9; 11 Participants
Phase 2 N=84 Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke
Acute Cerebral Stroke Within 12 Hours for the First Time
Primary: National Institutes of Health Stroke Scale Score — 8.78; 7.80; 8.85; 5.48 units on a scale
Phase 2 N=195 Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation
Ischemic Stroke · Transient Ischemic Attack
Primary: Number of Participants With Intracranial Bleeding and/or Recurrent Ischemic Lesion as Confirmed by MRI Imaging — 47; 48 Participants
N/A N=80 Deep Learning Enabled Endovascular Stroke Therapy Screening in Community Hospitals
Acute Ischemic Stroke (AIS)
Primary: Time From Emergency Room Arrival to Initiation of Endovascular Stroke Therapy ("Door-to-groin" Time) — 100; 88 minutes
N/A N=206 Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo
Ischemic Stroke
Primary: Weighted Modified Rankin Scale (mRS) Score, Lead Co-Primary Efficacy Outcome — 5.5; 3.4 score on a scale
Phase 3 N=514 Multi-arm Optimization of Stroke Thrombolysis
Acute Ischemic Stroke
Primary: 90-day Utility Weighted Modified Rankin Scores (UW-mRS) — 5.2; 6.3; 6.8 score on a scale — p=0.002
Phase 3 N=850 Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
Stroke, Acute
Primary: Number of Participants With Independent Functioning on the Modified Rankin Scale (mRS), as Defined by a Score of 0-2 — 181; 206 Participants
Phase 2 N=161 Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
Acute Ischemic Stroke
Primary: Change in Infarct Volume From Baseline (Diffusion-Weighted Imaging [DWI]) to Day 5 (Fluid-Attenuated Inversion Recovery [FLAIR]) — 2.17; 2.37 mL — p=0.779
Phase 2 N=18 Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Ischemic Stroke
Primary: Symptomatic Intracerebral Hemorrhage (ICH) — 1; 1 participants
Phase 2 N=27 Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Stroke · Brain Infarction
Primary: The Number of Patients Who Experience Symptomatic Intracerebral Hemorrhage (sICH). — 1 participants
Phase 4 N=108 Assess the Penumbra System in the Treatment of Acute Stroke
Ischemic Stroke
Primary: Good Functional Outcome as Defined by a Modified Rankin Score of 0-2 — 14; 19 Participants
N/A N=400 Investigation of Clot in Ischemic Stroke and Hematoma Evacuation
Ischemic Stroke · Intracranial Hematoma
Primary: Clot Specimen Histology — 373; 12 Count of specimen
N/A N=984 Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry
Ischemic Stroke
Primary: Number of Participants Assessed for Revascularization With mTICI Grades 2b-3 — 724 Participants